TY - JOUR
T1 - Mode of detection and breast cancer mortality by follow-up time and tumor characteristics among screened women in Cancer Prevention Study-II
AU - Puvanesarajah, Samantha
AU - Gapstur, Susan M.
AU - Patel, Alpa V.
AU - Sherman, Mark E.
AU - Flanders, W. Dana
AU - Gansler, Ted
AU - Troester, Melissa A.
AU - Gaudet, Mia M.
N1 - Funding Information:
Dr. Puvanesarajah was supported by the American Cancer Society’s Cancer Prevention Studies Post-Doctoral Fellowship Program. The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II cohort. Acknowledgements Disclaimer
Funding Information:
The authors express sincere appreciation to all Cancer Prevention Study participants, and to each member of the study and biospecimen management group. The authors would like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention’s National Program of Cancer Registries and cancer registries supported by the National Cancer Institute’s Surveillance Epidemiology and End Results Program.
Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Purpose: In a screened population, breast cancer-specific mortality is lower for screen-detected versus symptom-detected breast cancers; however, it is unclear whether this association varies by follow-up time and/or tumor characteristics. To further understand the prognostic utility of mode of detection, we examined its association with breast cancer-specific mortality, overall and by follow-up time, estrogen receptor status, tumor size, and grade. Methods: In the Cancer Prevention Study-II Nutrition Cohort, 3975 routinely screened women were diagnosed with invasive breast cancer (1992–2015). Among 2686 screen-detected and 1289 symptom-detected breast cancers, 206 and 209 breast cancer deaths, respectively, occurred up to 24 years post diagnosis. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated from Cox proportional hazard regression models. Results: Controlling for prognostic factors, symptom detection was associated with higher risk of breast cancer-specific death up to 5 years after diagnosis (HR≤5years = 1.88, 95% CI 1.21–2.91) this association was attenuated in subsequent follow-up (HR>5years = 1.26, 95% CI 0.98–1.63). Within tumor characteristic strata, there was a 1.3–2.7-fold higher risk of breast cancer death associated with symptom-detected cancers ≤ 5 years of follow-up, although associations were only significant for women with tumors < 2 cm (HR≤5years = 2.42, 95% CI 1.19–4.93) and for women with grade 1 or 2 tumors (HR≤5years = 2.72, 95% CI 1.33–5.57). In subsequent follow-up, associations were closer to the null. Conclusions: Screen detection is a powerful prognostic factor for short-term survival. Among women who survived at least 5 years after breast cancer diagnosis, other clinical factors may be more predictive of breast cancer survival.
AB - Purpose: In a screened population, breast cancer-specific mortality is lower for screen-detected versus symptom-detected breast cancers; however, it is unclear whether this association varies by follow-up time and/or tumor characteristics. To further understand the prognostic utility of mode of detection, we examined its association with breast cancer-specific mortality, overall and by follow-up time, estrogen receptor status, tumor size, and grade. Methods: In the Cancer Prevention Study-II Nutrition Cohort, 3975 routinely screened women were diagnosed with invasive breast cancer (1992–2015). Among 2686 screen-detected and 1289 symptom-detected breast cancers, 206 and 209 breast cancer deaths, respectively, occurred up to 24 years post diagnosis. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated from Cox proportional hazard regression models. Results: Controlling for prognostic factors, symptom detection was associated with higher risk of breast cancer-specific death up to 5 years after diagnosis (HR≤5years = 1.88, 95% CI 1.21–2.91) this association was attenuated in subsequent follow-up (HR>5years = 1.26, 95% CI 0.98–1.63). Within tumor characteristic strata, there was a 1.3–2.7-fold higher risk of breast cancer death associated with symptom-detected cancers ≤ 5 years of follow-up, although associations were only significant for women with tumors < 2 cm (HR≤5years = 2.42, 95% CI 1.19–4.93) and for women with grade 1 or 2 tumors (HR≤5years = 2.72, 95% CI 1.33–5.57). In subsequent follow-up, associations were closer to the null. Conclusions: Screen detection is a powerful prognostic factor for short-term survival. Among women who survived at least 5 years after breast cancer diagnosis, other clinical factors may be more predictive of breast cancer survival.
KW - Breast
KW - Breast neoplasms/mortality
KW - Epidemiology
KW - Mammography
KW - Survival analysis
UR - http://www.scopus.com/inward/record.url?scp=85068799213&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068799213&partnerID=8YFLogxK
U2 - 10.1007/s10549-019-05322-9
DO - 10.1007/s10549-019-05322-9
M3 - Article
C2 - 31264062
AN - SCOPUS:85068799213
SN - 0167-6806
VL - 177
SP - 679
EP - 689
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 3
ER -